Ai Industry Insights

Industry Insights: AI 15th July

Industry Insights: AI 15th July

  • Reading time:2 mins read

This week’s insights highlight three of the latest findings in the application of artificial intelligence (AI) in the healthcare and pharmaceutical industries.


AI-supported diabetes platform linked to weight loss

Recent research has found that an AI-powered glucose monitoring (CGM) platform may support meaningful weight loss in adults with type 2 diabetes. The platform combines CGM data with AI-generated personalised lifestyle recommendations to help users understand how diet, activity and habits affect glucose levels.

According to the study, participants who engaged consistently with the platform experienced greater weight loss than less active users, suggesting that AI may successfully complement traditional diabetes care. The authors, however, noted that further research is necessary to confirm the findings.

Opportunities and challenges for AI in sleep medicine

The annual SLEEP 2026 conference recently gathered sleep medicine experts who explored the role of AI in sleep medicine.

The potential of AI to improve diagnostic efficiency and reduce workload in the field has been a highly debated topic. Speakers highlighted important challenges that require attention before implementing AI in the clinic, such as algorithm bias, limited external validation, data privacy, and the need for clear regulations.

A recurring message throughout the discussions was that AI should support clinical expertise, but not replace it.

AI chatbots still struggle with colorectal cancer information

Artificial intelligence may not always get it right. A recent study evaluating popular AI chatbots found that they scored below 28% on average on colorectal cancer-related questions, a sub-optimal performance.

The study showed that chatbot responses were understandable and well-structured; however, researchers identified factual inaccuracies, incomplete information, and inconsistent recommendations.

These findings reinforce that AI chatbots cannot be considered standalone sources of medical advice. Instead, they may serve as supplementary educational tools, provided that information is reviewed and verified by qualified healthcare professionals.

For more industry insights visit elion.nz/insights/

Want to get in touch? Contact us today at https://elion.nz/get-in-touch/

Elion Medical Communications